Vertex Pharmaceuticals (VRTX) reported Q4 non-GAAP net income late Monday of $3.98 per diluted share, down from $4.20 a year earlier.
Analysts polled by FactSet expected $4.02.
Product revenue for the quarter ended Dec. 31 was $2.91 billion, up from $2.52 billion a year earlier.
Analysts surveyed by FactSet forecast $2.78 billion.
The biotech firm expects fiscal 2025 revenue of $11.75 billion to $12 billion. Analysts polled by FactSet are looking for $11.84 billion.
Shares of Vertex Pharmaceuticals were up 1.2% in after-hours trading.
免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。